America's vanishing science jobs (New York Post)
By Jonathan (Josh) Bloom, Ph.D.
Type : Editorial
Publish Date : Friday, June 24, 2011
By Dr. Josh Bloom. After earning my PhD, in chemistry, I worked in drug-discovery research for more than 20 years. Aside from being a fascinating profession, it was pretty secure -- until the last decade. Then it became anything but.  Read Full >>

How Far We’ve Come in the Battle Against AIDS (Medical Progress Today)
Type : Editorial
Publish Date : Friday, June 24, 2011
By Dr. Josh Bloom. We may not realize it now, but at some future date the world will look back and recognize May 2011 as a remarkable turning point in the history of the struggle against AIDS.  Read Full >>

Immunity: when it's smart to go with the herd (Guardian)
By Gilbert Ross, M.D., Dr. Henry Miller
Type : Editorial
Publish Date : Monday, June 13, 2011
By Dr. Henry Miller and Dr. Gilbert Ross. Infectious diseases that used to claim the lives of one in six children before their fifth year are making an alarming comeback in the US. The culprits are parents who should know better – and the politicians who bend over backwards to accommodate them.   Read Full >>

Will Rationing Supersede America's Healthcare Legacy? (Medical News Today)
By Gilbert Ross, M.D.
Type : Editorial
Publish Date : Thursday, March 24, 2011
By Dr. Gilbert Ross. We all like to think of America as a land of opportunity, a place where people are free to make their own choices in matters large and small. That's why it's so disturbing to see American regulators moving to restrict the treatment options of women suffering from advanced-stage "triple-negative" breast cancer, the most difficult type to treat - and doing so at the same time European regulators are reinforcing the choices available for treatment.    Read Full >>

The NIH on Drugs (The Daily Caller)
By Jonathan (Josh) Bloom, Ph.D.
Type : Editorial
Publish Date : Wednesday, March 2, 2011
By Dr. Josh Bloom. In late January, Obama administration officials announced that they were very concerned about the slow race of new drugs coming from the pharmaceutical industry. They should be concerned. The number of new chemical entities (NCEs) launched in recent years is near historic lows. And there are many unmet medical needs for which no therapies are available or on the horizon.  Read Full >>